Literature DB >> 23899277

The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate.

Jeremie Guedj, Harel Dahari, Susan L Uprichard, Alan S Perelson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23899277      PMCID： PMC4067513          DOI： 10.1586/17474124.2013.811050

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN： 1747-4124            Impact factor:   3.869


× No keyword cloud information.
  13 in total

1.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.

Authors:  Joseph F Perz; Gregory L Armstrong; Leigh A Farrington; Yvan J F Hutin; Beth P Bell
Journal:  J Hepatol       Date:  2006-06-23       Impact factor: 25.083

2.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

Authors:  A U Neumann; N P Lam; H Dahari; D R Gretch; T E Wiley; T J Layden; A S Perelson
Journal:  Science       Date:  1998-10-02       Impact factor: 47.728

3.  Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials.

Authors:  Tahany Awad; Kristian Thorlund; Goran Hauser; Davor Stimac; Mahasen Mabrouk; Christian Gluud
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

4.  The global health burden of hepatitis C virus infection.

Authors:  Francesco Negro; Alfredo Alberti
Journal:  Liver Int       Date:  2011-07       Impact factor: 5.828

5.  Robust hepatitis C virus infection in vitro.

Authors:  Jin Zhong; Pablo Gastaminza; Guofeng Cheng; Sharookh Kapadia; Takanobu Kato; Dennis R Burton; Stefan F Wieland; Susan L Uprichard; Takaji Wakita; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-06       Impact factor: 11.205

6.  Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.

Authors:  Jeremie Guedj; Alan S Perelson
Journal:  Hepatology       Date:  2011-05-02       Impact factor: 17.425

7.  Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells.

Authors:  Bruno Sainz; Francis V Chisari
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 8.  Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?

Authors:  Anushree Chatterjee; Jeremie Guedj; Alan S Perelson
Journal:  Antivir Ther       Date:  2012-10-05

9.  Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

Authors:  Edward J Gane; Catherine A Stedman; Robert H Hyland; Xiao Ding; Evguenia Svarovskaia; William T Symonds; Robert G Hindes; M Michelle Berrey
Journal:  N Engl J Med       Date:  2013-01-03       Impact factor: 91.245

10.  Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

Authors:  Min Gao; Richard E Nettles; Makonen Belema; Lawrence B Snyder; Van N Nguyen; Robert A Fridell; Michael H Serrano-Wu; David R Langley; Jin-Hua Sun; Donald R O'Boyle; Julie A Lemm; Chunfu Wang; Jay O Knipe; Caly Chien; Richard J Colonno; Dennis M Grasela; Nicholas A Meanwell; Lawrence G Hamann
Journal:  Nature       Date:  2010-04-21       Impact factor: 49.962
View more
  5 in total

1.  Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics.

Authors:  Vladimir Reinharz; Harel Dahari; Danny Barash
Journal:  Math Biosci       Date:  2018-03-15       Impact factor: 2.144

Review 2.  Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.

Authors:  Sheng-Shun Yang; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2015-11-05       Impact factor: 6.047

3.  Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition.

Authors:  James H Nettles; Richard A Stanton; Joshua Broyde; Franck Amblard; Hongwang Zhang; Longhu Zhou; Junxing Shi; Tamara R McBrayer; Tony Whitaker; Steven J Coats; James J Kohler; Raymond F Schinazi
Journal:  J Med Chem       Date:  2014-11-03       Impact factor: 7.446

4.  A Robust and Efficient Numerical Method for RNA-Mediated Viral Dynamics.

Authors:  Vladimir Reinharz; Alexander Churkin; Harel Dahari; Danny Barash
Journal:  Front Appl Math Stat       Date:  2017-10-31

5.  Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies.

Authors:  Vyas Ramanan; Kartik Trehan; Mei-Lyn Ong; Joseph M Luna; Hans-Heinrich Hoffmann; Christine Espiritu; Timothy P Sheahan; Hamsika Chandrasekar; Robert E Schwartz; Kathleen S Christine; Charles M Rice; Alexander van Oudenaarden; Sangeeta N Bhatia
Journal:  Virology       Date:  2016-04-27       Impact factor: 3.616
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.